Expression analysis and in silico characterization of intronic long noncoding RNAs in renal cell carcinoma: emerging

Angela A Fachel, Ana C Tahira, Santiago A Vilella-Arias

  • 1Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, 05508-900 São Paulo, SP, Brazil. verjo@iq.usp.br.

Molecular Cancer
|November 19, 2013
PubMed
Abstract

Insights

Intronic long noncoding RNAs (lncRNAs) are altered in renal cell carcinoma (RCC). These conserved RNAs may play a role in kidney cancer development and progression.

Area of Science:

  • Genomics
  • Molecular Biology
  • Oncology

Background:

  • Intronic and intergenic long noncoding RNAs (lncRNAs) are emerging gene expression regulators.
  • The molecular pathogenesis of renal cell carcinoma (RCC) is poorly understood, with limited studies on intronic lncRNAs in RCC.

Purpose of the Study:

  • To investigate the role of intronic lncRNAs in renal cell carcinoma (RCC).
  • To identify intronic lncRNA signatures associated with RCC and patient survival.
  • To explore the regulatory functions and epigenetic modifications of intronic lncRNAs in RCC.

Main Methods:

  • Microarray analysis of intronic lncRNAs in 18 primary RCC tumors and 11 matched nontumor tissues.
  • Meta-analysis with public data for expression, epigenetic marks, and conserved sequences.
  • Correlation analysis between lncRNA and mRNA expression, and module map analysis for protein-coding genes.

Main Results:

  • Identified a signature of 29 intronic lncRNAs differentially expressed in RCC.
  • Found a signature of 26 intronic lncRNAs correlating with five-year patient survival.
  • Discovered 4303 intronic antisense lncRNAs in RCC, with 22% cis-correlated to mRNA expression; 60% were evolutionarily conserved and associated with epigenetic marks.

Conclusions:

  • Intronic antisense lncRNAs are widely expressed and altered in RCC tumors.
  • These conserved lncRNAs, potentially modulated by epigenetics, may contribute to renal cell malignant transformation.